At a glance
| Known as | ORX489 |
|---|---|
| Sponsor | Centessa Pharmaceuticals — a wholly owned subsidiary of Eli Lilly since 24 Jun 2026 |
| Mechanism | Orexin receptor 2 (OX2R) agonist |
| Stage | Phase 1 |
| Indications | Neuropsychiatric |
| Registered trials | 1 · 1 recruiting |
| Last verified | 4 Aug 2026 |
Where it stands
ORX489 is Centessa's most potent OX2R agonist to date and is being developed for neuropsychiatric disorders — again, a target outside the sleep-disorder core of this class.
It has moved past the IND-enabling stage it previously sat at and is now in a Phase 1 study in healthy adults.
Registered trials
All 1 study on ClinicalTrials.gov that name ORX489 or its development code, pulled from the registry on 4 Aug 2026.
| Registry ID | Study | Phase | Status | Primary completion |
|---|---|---|---|---|
NCT07413666 |
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 YearsHealthy adults. Recruiting.212 participants | Phase 1 | Recruiting | 30 Jun 2027 |
Trial records are maintained by the sponsor and change without notice. Follow each link for current recruitment status and eligibility.
ORX489 — common questions
What is ORX489 being developed for?
Neuropsychiatric disorders. Centessa describes it as its most potent OX2R agonist to date.
What phase is ORX489 in?
Phase 1. Study NCT07413666 is running in healthy adults, having moved past the IND-enabling stage the compound previously sat at.
Source
This entry was last checked against its primary source on 4 Aug 2026: https://clinicaltrials.gov/study/NCT07413666
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ORX489 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.